SURPASS® (1% diclofenac sodium) Topical Anti-Inflammatory Cream is indicated for the control of pain and inflammation associated with osteoarthritis (OA) in tarsal, carpal, metacarpophalangeal, metatarsophalangeal and proximal interphalangeal (hock, knee, fetlock and pastern) joints in horses.

• SURPASS doesn’t just modify the symptoms of osteoarthritis, it also modifies the disease itself²
• Enhanced delivery through skin barrier – via patented multi-layered liposomal delivery technology^1,2
• Sustained release of relief for 12 hours
• Apply two times per day³ four to six times or more with other topicals labeled for humans
• Targeted, lower drug levels for reduced systemic uptake and reduced potential for side effects³

1. Caldwell FJ, Mueller PO, Lynn RC, Budsberg SC. Effect of topical application of diclofenac liposomal suspension on experimentally induced subcutaneous inflammation in horses. Am J Vet Res. 2004;65(3):271–276.
2. Frisbie DD, McIlwraith CW, Kawcak CE, Werpy NM, Pearce GL. Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res. 2009;70(2):210–215.
3. SURPASS (1% diclofenac sodium) [Freedom of Information Summary]. Greensboro, NC: IDEXX Pharmaceuticals, Inc.; 2004.

SURPASS® (1% diclofenac sodium) Topical Anti-Inflammatory Cream contains 1% diclofenac sodium contained in the WISDOM® Liposomal formulation. Diclofenac is a prescription non-narcotic, nonsteroidal anti-inflammatory drug (NSAID) used for the control of pain and inflammation associated with osteoarthritis (OA) in hock, knee, fetlock or pastern joints in horses.

Adverse reactions associated with NSAIDs may include: weight loss, colic, diarrhea, or yellowing of the gums, skin, or whites of the eyes (jaundice). Serious adverse reactions associated with this drug class can occur without warning and, in rare situations, result in death. Discontinue the use of SURPASS® (1% diclofenac sodium) Topical Anti-Inflammatory Cream and contact your veterinarian immediately if these signs are observed. The majority of patients with drug-related reactions recover when the signs are recognized, drug administration is stopped, and veterinary care, if appropriate, is initiated. Adverse reactions during the safety study included a gastric ulcer in one horse that received 5.6x the recommended dosage, diarrhea and uterine discharge in one horse that received 2.8x the recommended dosage, and weight loss in four of the six horses in the 5.6x dosage group.

1% Diclofenac Sodium

Contact your nearest emergency animal hospital.

Exceeding the recommended dosage or treating multiple joints may increase plasma concentrations of diclofenac. The systemic effects of excess diclofenac doses that exceed the recommended label amount and duration have not been evaluated. As a class, NSAIDs may be associated with gastrointestinal and renal toxicity. When NSAIDs inhibit prostaglandins that cause inflammation, they may also inhibit prostaglandins that maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or preexisting disease more often than in healthy patients. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular and/or hepatic dysfunction. Horses should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data before and periodically during administration of any NSAID. Owners should be advised to observe for signs of potential drug toxicity. Studies to determine the effect of SURPASS® (1% diclofenac sodium) Topical Anti-Inflammatory Cream when administered concomitantly with other drugs have not been conducted. Since many NSAIDs possess the potential to induce gastric ulceration, concomitant use of SURPASS cream with any other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided. Drug compatibility should be monitored closely in patients receiving adjunctive therapy. SURPASS topical cream is contraindicated in animals with known hypersensitivity to diclofenac.

SURPASS® (1% diclofenac sodium) Topical Anti-Inflammatory Cream is packaged in 124-gram trilaminate tubes.

Boehringer Ingelheim